Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)

Supporting evidence

• Other supporting evidence

• National Disease Registration Service data review on tisagenlecleucel (PDF 295 KB)

  Published:

  29 November 2023